HeartSine hit with Class I over defibrillator recall

HeartSine is warning of a potentially fatal glitch in its Samaritan defibrillator--courtesy of HeartSine

HeartSine launched a global recall of its Samaritan defibrillators after 5 deaths possibly related to a malfunction in the devices, and the FDA has slapped the affair with its most serious label, warning of serious injury or fatality.

In September, the Irish devicemaker launched a worldwide correction, warning customers that some Samaritan 300/300P models had been found to intermittently switch on and off, depleting the battery and possibly rendering them inoperable during a cardiac event. Furthermore, some devices have a software glitch that can misinterpret battery life and shut the unit off unnecessarily.

HeartSine says it hasn't received any reports of deaths tied directly to the malfunction, but it is investigating 5 fatalities that might be related. The FDA is asking patients and physicians to report adverse events through its online MedWatch system.

The company said it has sent backup power sources to affected customers, warning them to keep the reserves on hand should the device fail during a cardiac event.

The affected devices were manufactured between August 2004 and January 2011.

- read the FDA notice

Suggested Articles

About 10 months after first announcing the move, Google has finally subsumed the healthcare-focused efforts of DeepMind.

Amgen has tapped Adaptive Biotechnologies to deliver next-generation sequencing assays as it moves its blood cancer drugs toward approval.

Bayer led One Drop’s $40 million series B round and licensed its technology for its “bio-digital efforts” in areas such as cancer and heart disease.